Thailand Becomes the Sixth Country that Approves BIBP’s COVID-19 Vaccine for Registration and Marketing

On May 28 local time, Paisan Dankhum, Secretary General of the Food and Drug Administration (FDA) of Thailand, announced at a press conference that FDA had approved the application for registration of the Inactivated COVID-19 Vaccine (Vero Cell) developed and produced by Beijing Institute of Biological Products Co., Ltd. (BIBP), China National Biotec Group Company Limited (CNBG), Sinopharm (BIBP’s COVID-19 Vaccine).

      This approval makes Thailand the fifth PIC/S member state that grants access approval to BIBP’s COVID-19 vaccine, and the sixth country that approves the vaccine for registration in the world. Earlier, the vaccine has been approved for registration or conditional marketing in the UAE, Bahrain, China, Bolivia, Seychelles, respectively.

      The press conference was attended by the Minister of Public Health, the Director-general of FDA, and the Director-general of the Chulabhorn Royal Academy of Thailand, and other leaders. As of May 28, 2021, BIBP’s COVID-19 vaccine has been approved for registration and marketing or emergency use in 70 countries and regions worldwide, received the procurement requests from more than 100 countries and international organizations, vaccination has covered 196 country population. On May 7, BIBP's COVID-19 vaccine was included into the Emergency Use Listing (EUL) by the WHO. Since then, the Chinese vaccines will contribute more Chinese strength to the global fight against COVID-19.